Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel activation, increasing thrombosis risk. Similarly, CYP2D6 polymorphisms influence opioid metabolism, with poor metabolizers experiencing reduced analgesic effects from codeine and ultrarapid metabolizers facing morphine toxicity risks.
Drug receptor polymorphisms modify drug interactions. VKORC1 variants significantly affect warfarin dosing, with rare variants causing resistance and common variants altering dose requirements across populations. UGT1A1 *28 polymorphism increases the toxicity of irinotecan, requiring careful dose adjustments.
The biologic milieu, influenced by genetic variations, further affects drug response. MTHFR mutations may elevate homocysteine levels, which have been associated with increased thrombosis risk in some studies, though the clinical significance remains debated. TYMS polymorphisms impact methotrexate efficacy and toxicity. Variations in serotonin and β-adrenergic receptors influence responses to antidepressants and asthma medications, respectively.
Although not direct drug targets, ion channel polymorphisms contribute to arrhythmia risks. Variants in KCNQ1, KCNE1, and KCNE2 can prolong baseline QT intervals, making individuals more susceptible to drug-induced cardiac arrhythmias. This effect is particularly relevant when using antiarrhythmics, macrolide antibiotics, or antihistamines.
Multiple genetic factors, along with environmental influences, shape drug responses. Some high-risk genetic variations lead to severe disease phenotypes, while others modulate pharmacodynamics and pharmacokinetics in more subtle ways. For instance, polymorphisms in HMG-CoA reductase affect statin efficacy in lowering LDL cholesterol. Additionally, variations in coagulation-related genes, such as MTHFR, factor V, and prothrombin, modulate thrombosis risk in the presence of prothrombotic drugs.
Understanding these genetic influences enables personalized medicine approaches, optimizing drug efficacy while minimizing adverse effects. Identifying genetic variants can guide dosage adjustments and therapeutic strategies, ensuring safer and more effective treatment plans.
Genetic variations influence drug response through pharmacokinetics, receptor interactions, and the biologic milieu.
Pharmacokinetic alterations affect drug concentration.
For instance, individuals with the non-functional CYP2C9 variant require lower warfarin doses due to an increased bleeding risk. Similarly, the CYP2C19 variant impairs clopidogrel activation, leading to a higher risk of thrombosis.
Drug receptor variations also modify the response.
For instance, TYMS polymorphisms with the 2R/2R genotype can impact treatment outcomes. They affect both the toxicity and efficacy of anticancer agents that target TYMS.
Modifications in the biologic milieu also alter drug response. For example, MTHFR polymorphisms elevate homocysteine levels, increasing the risk of thrombosis.
Polymorphisms in ion channels, although not direct drug targets, prolong baseline QT intervals, increasing susceptibility to cardiac arrhythmias.
This predisposition is particularly concerning when using antiarrhythmics or certain noncardiovascular drugs.
繁體中文
